Aptevo Therapeutics (APVO) Common Equity (2016 - 2025)
Aptevo Therapeutics (APVO) has disclosed Common Equity for 11 consecutive years, with $17.4 million as the latest value for Q3 2025.
- Quarterly Common Equity rose 293.48% to $17.4 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $17.4 million through Sep 2025, up 293.48% year-over-year, with the annual reading at $4.8 million for FY2024, 61.09% down from the prior year.
- Common Equity hit $17.4 million in Q3 2025 for Aptevo Therapeutics, up from $6.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $23.3 million in Q1 2023 to a low of -$5.9 million in Q1 2022.
- Historically, Common Equity has averaged $10.1 million across 5 years, with a median of $10.5 million in 2021.
- Biggest YoY gain for Common Equity was 1378.12% in 2022; the steepest drop was 156.02% in 2022.
- Year by year, Common Equity stood at $1.2 million in 2021, then surged by 1378.12% to $18.0 million in 2022, then crashed by 32.01% to $12.2 million in 2023, then tumbled by 61.09% to $4.8 million in 2024, then surged by 265.76% to $17.4 million in 2025.
- Business Quant data shows Common Equity for APVO at $17.4 million in Q3 2025, $6.5 million in Q2 2025, and -$1.5 million in Q1 2025.